STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [144] Spyre Therapeutics, Inc. SEC Filing

Spyre officer to sell $4.2M in stock via options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. (SYRE) received a Rule 144 notice indicating that officer Heidy King-Jones plans to sell up to 46,665 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with sales planned beginning on or about 09/01/2026.

The shares were and will be acquired upon the exercise of stock options over the next three months, with the dates of acquisition and payment matching the exercise/sale dates. The filing lists an aggregate market value of approximately $4,168,584.45 for the shares and notes 88,173,762 shares outstanding as of 09/01/2026.

Positive

  • None.

Negative

  • None.
Shares to be sold 46,665 shares Common stock covered by Rule 144 notice
Aggregate market value $4,168,584.45 Market value of 46,665 shares to be sold
Shares outstanding 88,173,762 shares Common shares outstanding as of 09/01/2026
Planned sale start date 09/01/2026 Date listed for securities information and sales
Shares underlying planned option exercises 46,665 shares Options to be exercised over next three months
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Form 144 regulatory
"144: Filer Information 144: Issuer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Exercise of Stock Options financial
"Common | 09/01/2026 | Exercise of Stock Options | Issuer"
aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC ... | 46665 | 4168584.45"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What does the Form 144 filing disclose for Spyre Therapeutics (SYRE)?
It discloses that officer Heidy King-Jones plans to sell up to 46,665 shares of Spyre Therapeutics common stock under Rule 144, with shares obtained through stock option exercises and sales expected to begin around 09/01/2026.

How many SYRE shares are planned to be sold under this Form 144?
The notice covers up to 46,665 shares of Spyre Therapeutics common stock. The securities are associated with the planned exercise of stock options over a three-month period, with sales reported under Rule 144.

What is the aggregate market value of the SYRE shares in this Form 144?
The Form 144 lists an aggregate market value of approximately $4,168,584.45 for the 46,665 shares of Spyre Therapeutics common stock covered by the planned Rule 144 sales.

How will the Spyre Therapeutics (SYRE) shares be acquired for sale?
The shares will be acquired upon the exercise of stock options. The remarks state that the securities to be sold were and will be received through stock option exercises over the next three months, with acquisition and payment dates matching the exercise/sale dates.

What is the stated shares outstanding figure for SYRE in this filing?
The Form 144 notes that 88,173,762 shares of Spyre Therapeutics common stock were outstanding as of 09/01/2026. This figure serves as context and is separate from the 46,665 shares covered by the notice.

Who is the broker for the planned SYRE share sales under Form 144?
The planned sales will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY, as listed for the common stock in the Form 144 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR